NBHL and FRONTEO Enter PoC Research Agreement to Accelerate Antibody Drug Discovery Leveraging AI and GPCR Antibody Platforms

News Release_NBHL and FRONTEO Signed PoC Research Agreements

This collaboration will harness FRONTEO’s Drug Discovery AI Factory (DDAIF), an AI-powered drug discovery support platform, alongside NBHL’s proprietary MoGRAA platform for GPCR-targeted antibody discovery.

Under this agreement, the two companies will combine DDAIF’s capability to discover previously unreported disease-associated target molecules with MoGRAA’s strength in efficiently discovering highly selective antibodies against GPCRs, which have been difficult targets through conventional drug discovery approaches. The integration of these technologies aims to accelerate the development of innovative therapeutics targeting GPCRs.

By advancing this initiative, NBHL and FRONTEO will leverage their complementary expertise and technologies to address unmet medical needs. The collaboration aspires to contribute to the realization of groundbreaking new therapies and to the improvement of patients’ quality of life (QOL).